Bio-Rad outlines flat to 1% currency-neutral revenue growth for 2025 while expanding ddPCR partnerships

2 days ago 4

Earnings Call Insights: Bio-Rad Laboratories, Inc. (BIO) Q3 2025

Management View

  • Jonathan DiVincenzo, President & COO, reported that "revenue was consistent with our outlook and operating margin exceeded consensus, a testament to the discipline and agility of our teams in what continues to be a challenging

Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed.

Please see full earnings call transcripts

here.

The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

Read Entire Article